Physician profile
Michael Malouf
NPI 1578549234
$1,698.59
in general payments reported to CMS, 2019-2025
21 companies · $259 in 2025
The $259 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,101 · 2020: $231 · 2021: $94.39 · 2023: $13.85 · 2025: $259.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $273.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $273.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $289.75 | 2019-2025 | Zepbound, Mounjaro |
| Pfizer INC. | $254.56 | 2019-2025 | |
| Novo Nordisk INC | $180.19 | 2019-2025 | Wegovy, Ozempic |
| Sanofi-Aventis U.S. LLC | $170.06 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $137.12 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $95.49 | 2019-2025 | Jardiance |
| Allergan, INC. | $85.77 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $68.72 | 2019-2020 | |
| Exact Sciences Corporation | $55.10 | 2025 | The Cologuard Plus Collection Kit |
| Novartis Pharmaceuticals Corporation | $52.14 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $50.28 | 2019-2023 | Xifaxan |
| Abbott Laboratories | $46.10 | 2025 | Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals LP | $42.14 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $34.63 | 2019 | |
| Nevro Corp. | $29.34 | 2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Depuy Synthes Sales INC. | $26.51 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $20.33 | 2019 | |
| Gilead Sciences, INC. | $19.37 | 2019 | |
| Amgen INC. | $15.43 | 2025 | Repatha, Otezla |
| Abbvie INC. | $13.80 | 2021 | |
| Sanofi Pasteur INC. | $11.76 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Malouf listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.